Extrapulmonary neoplasms in lung cancer screening

Area of Science:

• Oncology
• Radiology
• Public Health

Background:

• National Lung Screening Trial (NLST) demonstrated reduced lung cancer mortality with low-dose computed tomography (LDCT) screening.
• Lung cancer screening (LCS) identifies incidental findings beyond lung cancer, including cardiovascular and pulmonary diseases.
• Extrapulmonary malignancies represent a significant proportion of deaths in LDCT screening participants.

Purpose of the Study:

• To review the prevalence of incidentally detected extrapulmonary malignancies during lung cancer screening.
• To discuss the clinical relevance and management strategies for these incidental findings.
• To evaluate the potential impact of early diagnosis of extrapulmonary malignancies on overall morbidity and mortality.

Main Methods:

• Review of data from the National Lung Screening Trial (NLST).
• Analysis of mortality rates related to lung cancer and extrapulmonary malignancies.
• Literature review on the prevalence, clinical significance, and management of incidental findings.

Main Results:

• LDCT screening significantly reduces lung cancer-specific mortality.
• A substantial percentage of deaths in the CT arm of NLST were attributed to extrapulmonary malignancies.
• Incidental detection of various extrapulmonary neoplasms (thyroid, breast, kidney, etc.) is possible during LCS.

Conclusions:

• Early diagnosis and treatment of clinically significant incidental findings, including extrapulmonary malignancies, may further decrease morbidity and mortality in screening participants.
• Lung cancer screening offers a valuable opportunity for the early detection of a wide range of serious health conditions.
• Further research into the management of incidental findings during LCS is warranted to optimize patient outcomes.